Primary Objective:
- To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal
cell cancer (RCC). Clinical activity will take into account response rate and
progression free survival (PFS).
Secondary Objectives:
- To determine the toxicity of Pemetrexed + Gemcitabine in non-clear cell RCC.
- To estimate the survival rate of patients with non-clear cell RCC treated with this
combination.